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Radiofrequency catheter ablation has become a first-line cur-
ative therapy for the majority of the common forms of
supraventricular tachycardia, and for some forms of ventricular
tachycardia (VT). For example, VT occurring in the absence of
structural heart disease such as idiopathic left VT or right
ventricular outflow tract tachycardia can now be cured by
radiofrequency catheter ablation with a high degree of efficacy
and safety (1–6). In contrast, ablation of VT in patients with
underlying structural heart disease has not yet been widely
accepted as safe and effective. In this issue of the Journal,
Ellison et al. (7) expand on the role of radiofrequency catheter
ablation for the treatment of VT with a report on their clinical
experience using entrainment pace mapping to guide radiofre-
quency catheter ablation of VT in patients with arrhythmo-
genic right ventricular dysplasia (ARVD). The authors de-
scribe a small series of five patients who presented with
sustained, symptomatic VT. None of the patients had a history
of syncope or ventricular fibrillation. The diagnosis of ARVD
was based on the presence of electrocardiogram abnormalities,
right ventricular enlargement and/or hypokinesis on echocar-
diogram and inducible VT with a left bundle branch block
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pattern. A total of 19 morphologically different VTs were
induced. Pacing entrainment was performed from 58 sites in a
manner similar to that previously described by the authors and
others for mapping and ablation of VT in patients with
ischemic VT. The VT was noted to terminate during ablation
at 13 of 58 sites, mostly sites in the inferior-basal right ventricle
near the tricuspid annulus or in the right ventricular outflow
tract. In all, 8 of 19 VTs were ablated (i.e., terminated and not
reinducible) without complications. Although four of five
patients still had inducible VT after ablation, it appears from
the results that none has had a spontaneous recurrence of VT
in follow-up (mean 17 months) despite the fact that four of five
patients were previously refractory to one or more antiarrhyth-
mic drugs. During follow-up, one patient was off all treatment,
three patients were on antiarrhythmic drugs (primarily amio-
darone) and one had an implantable cardioverter defibrillator
(ICD) implanted. Thus, at first glance the results of ablation
appear encouraging. However, as the authors themselves point
out, this is a small series of patients with a relatively short
follow-up period. Consequently, the overall acute and long-
term safety and efficacy of radiofrequency catheter ablation for
VT in patients with ARVD may not be accurately represented
by this study.
The authors’ primary emphasis in this report, as suggested
by the title, was that VT in patients with ARVD shares many
features with VT in patients with ischemic heart disease and
myocardial infarction (8,9). For example, on the basis of
responses to entrainment, the VT in these five patients with
AVRD was determined to be due to reentry. Furthermore,
specific sites of interest in the VT reentrant circuit were
identified by entrainment (e.g., exit sites, central or proximal
areas of slow conduction, bystander sites, etc.) and used to
guide radiofrequency catheter ablation. However, the authors’
conclusion that entrainment can actually characterize the
anatomic and electrophysiologic nature of the VT reentry
circuits in ARVD may not be entirely supported by their data.
Such a complete characterization of the reentry circuits, as
suggested in their Figure 1, would probably require much more
extensive and detailed mapping than performed in this study.
This may explain in part the relative inaccuracy of entrainment
in predicting the efficacy of radiofrequency catheter ablation at
various sites in the VT reentry circuits in these patients. For
example, at exit and central/proximal sites where efficacy would
be expected to be high, only 25% and 50% of energy applica-
tions terminated VT, respectively. Furthermore, ablation at
outer loop and adjacent bystander sites, where efficacy might
be expected to be low, terminated VT during 25% of energy
applications. Thus, the relative inaccuracy of entrainment-
guided ablation in ARVD suggests that the VT reentrant
circuit may be more complex than shown in Figure 1. This
should not be surprising considering the complex and unpre-
dictable nature of the fibro-fatty infiltration of myocardium in
ARVD (10–13). It is also possible that epicardial reentry may
account for failure of ablation from the endocardial surface in
some cases.
Nonetheless, the fact that the authors have safely and
successfully mapped and ablated VT in some patients with
ARVD suggests yet another potential indication for radiofre-
quency catheter ablation. Similar success has been reported by
others, further supporting the authors’ observations (14–17).
However, the authors correctly acknowledge that the small
number of patients in their study is insufficient to assess
reasonably the risk of procedural complications and the long-
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term efficacy of ablation in patients with ARVD. These issues
must be carefully addressed, perhaps in the form of a large
multicenter trial or national registry, to delineate the role of
radiofrequency catheter ablation in the treatment of VT in
ARVD.
With respect to the risk of procedural complications, the
thinning of the right ventricular myocardium and replace-
ment with fibro-fatty infiltrates in ARVD raises concerns
regarding the possibility of perforation and pericardial tam-
ponade during ablation. There was no report of perforation in
this study, but the number of patients studied was small, as
the authors appropriately point out. The authors did not note
the use of magnetic resonance imaging (MRI) to determine
the extent of dysplasia in their patients. However, this diag-
nostic tool may be of some value in the diagnosis of ARVD
and in qualitative assessment of the extent of dysplasia and
thinning of the right ventricle (18 –20). Such information
may be useful in determining the safety of ablation vs.
medical or device therapy for VT in patients with ARVD.
Certainly in those patients with severe right ventricular
dysplasia and thinning on MRI, it may be prudent to
consider antiarrhythmic drug therapy (e.g., amiodarone) or
ICD implantation in lieu of ablation to avoid possible
procedural complications.
Of additional concern is the fact that patients with ARVD
may present anytime in the course of their disease with
syncopal VT or arrhythmic sudden death (21–32). Thus, while
the patients in this study had no history of syncope or aborted
sudden death, there is no assurance that they will not present
with a more serious or life-threatening episode of VT in the
future. Furthermore, since ARVD is typically a progressive
disease (10–13,33), new VTs could develop in the future
despite apparently successful ablation at present.
Finally, in this study the majority of patients were
continued on antiarrhythmic drugs therapy with amiodarone
or had an ICD implanted following ablation. Thus, ablation
was actually used as a palliative or adjunctive treatment as it
is usually used in ischemic VT (8,9). Therefore, although the
authors have shown the feasibility of mapping and ablating
VT in patients with ARVD, ablation as sole therapy should
probably not be condoned without a controlled trial com-
paring it with standard antiarrhythmic drug (e.g., amioda-
rone) or device (i.e., ICD) therapy to demonstrate at least
equivalent safety and efficacy.
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